Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy

M. Uchida, T. Nakamura, T. Shima, Y. Mori, G. Yoshimoto, K. Kato, M. Shimokawa, K. Hosohata, T. Miyamoto, K. Akashi

Research output: Contribution to journalArticle

Abstract

To assess compliance with the Japanese antiemetic guidelines for chemotherapy-induced nausea and vomiting (CINV), the frequencies of CINV occurrence and use of antiemetic rescue medications were examined in patients with hematological malignancy. A total of 40 patients with hematologic malignancy were eligible in this study. This study was performed in the Department of Hematology, Kyushu University Hospital, as a subgroup analysis from a nationwide, multicenter prospective cohort study conducted by the CINV Study Group of Japan. In the patients with hematological malignancy, the guideline compliance rate was 45 %. Five patients (22.7 %) experienced vomiting during the observation period after receiving non-guideline-consistent antiemetic prophylaxis, whereas no patient experienced vomiting after receiving guideline-consistent antiemetic prophylaxis. The study was not sufficiently powered to reach a statistical significance in its frequency of occurrence between the compliance and non-compliance groups. In the entire study period, 8 out of 40 patients required rescue medication, but there was no association between the status of compliance and the antiemetic guidelines. A total of 22 (55.0 %) patients achieved complete response, which was defined as no vomiting and no use of antiemetic rescue medication, during the study period. The rate of compliance with the prophylactic antiemetic treatment guidelines seemed to be low in patients with hematological malignancy, although the status of the guideline compliance did not always influence the antiemetic effects.

Original languageEnglish
Pages (from-to)250-254
Number of pages5
JournalPharmazie
Volume74
Issue number4
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Antiemetics
Hematologic Neoplasms
Nausea
Vomiting
Guidelines
Drug Therapy
Compliance
Hematology
Japan
Cohort Studies
Observation
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy. / Uchida, M.; Nakamura, T.; Shima, T.; Mori, Y.; Yoshimoto, G.; Kato, K.; Shimokawa, M.; Hosohata, K.; Miyamoto, T.; Akashi, K.

In: Pharmazie, Vol. 74, No. 4, 01.01.2019, p. 250-254.

Research output: Contribution to journalArticle

@article{87a56942ca8049c797f99bb12c63580e,
title = "Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy",
abstract = "To assess compliance with the Japanese antiemetic guidelines for chemotherapy-induced nausea and vomiting (CINV), the frequencies of CINV occurrence and use of antiemetic rescue medications were examined in patients with hematological malignancy. A total of 40 patients with hematologic malignancy were eligible in this study. This study was performed in the Department of Hematology, Kyushu University Hospital, as a subgroup analysis from a nationwide, multicenter prospective cohort study conducted by the CINV Study Group of Japan. In the patients with hematological malignancy, the guideline compliance rate was 45 {\%}. Five patients (22.7 {\%}) experienced vomiting during the observation period after receiving non-guideline-consistent antiemetic prophylaxis, whereas no patient experienced vomiting after receiving guideline-consistent antiemetic prophylaxis. The study was not sufficiently powered to reach a statistical significance in its frequency of occurrence between the compliance and non-compliance groups. In the entire study period, 8 out of 40 patients required rescue medication, but there was no association between the status of compliance and the antiemetic guidelines. A total of 22 (55.0 {\%}) patients achieved complete response, which was defined as no vomiting and no use of antiemetic rescue medication, during the study period. The rate of compliance with the prophylactic antiemetic treatment guidelines seemed to be low in patients with hematological malignancy, although the status of the guideline compliance did not always influence the antiemetic effects.",
author = "M. Uchida and T. Nakamura and T. Shima and Y. Mori and G. Yoshimoto and K. Kato and M. Shimokawa and K. Hosohata and T. Miyamoto and K. Akashi",
year = "2019",
month = "1",
day = "1",
doi = "10.1691/ph.2019.8889",
language = "English",
volume = "74",
pages = "250--254",
journal = "Die Pharmazie",
issn = "0031-7144",
publisher = "Govi-Verlag Pharmazeutischer Verlag GmbH",
number = "4",

}

TY - JOUR

T1 - Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy

AU - Uchida, M.

AU - Nakamura, T.

AU - Shima, T.

AU - Mori, Y.

AU - Yoshimoto, G.

AU - Kato, K.

AU - Shimokawa, M.

AU - Hosohata, K.

AU - Miyamoto, T.

AU - Akashi, K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - To assess compliance with the Japanese antiemetic guidelines for chemotherapy-induced nausea and vomiting (CINV), the frequencies of CINV occurrence and use of antiemetic rescue medications were examined in patients with hematological malignancy. A total of 40 patients with hematologic malignancy were eligible in this study. This study was performed in the Department of Hematology, Kyushu University Hospital, as a subgroup analysis from a nationwide, multicenter prospective cohort study conducted by the CINV Study Group of Japan. In the patients with hematological malignancy, the guideline compliance rate was 45 %. Five patients (22.7 %) experienced vomiting during the observation period after receiving non-guideline-consistent antiemetic prophylaxis, whereas no patient experienced vomiting after receiving guideline-consistent antiemetic prophylaxis. The study was not sufficiently powered to reach a statistical significance in its frequency of occurrence between the compliance and non-compliance groups. In the entire study period, 8 out of 40 patients required rescue medication, but there was no association between the status of compliance and the antiemetic guidelines. A total of 22 (55.0 %) patients achieved complete response, which was defined as no vomiting and no use of antiemetic rescue medication, during the study period. The rate of compliance with the prophylactic antiemetic treatment guidelines seemed to be low in patients with hematological malignancy, although the status of the guideline compliance did not always influence the antiemetic effects.

AB - To assess compliance with the Japanese antiemetic guidelines for chemotherapy-induced nausea and vomiting (CINV), the frequencies of CINV occurrence and use of antiemetic rescue medications were examined in patients with hematological malignancy. A total of 40 patients with hematologic malignancy were eligible in this study. This study was performed in the Department of Hematology, Kyushu University Hospital, as a subgroup analysis from a nationwide, multicenter prospective cohort study conducted by the CINV Study Group of Japan. In the patients with hematological malignancy, the guideline compliance rate was 45 %. Five patients (22.7 %) experienced vomiting during the observation period after receiving non-guideline-consistent antiemetic prophylaxis, whereas no patient experienced vomiting after receiving guideline-consistent antiemetic prophylaxis. The study was not sufficiently powered to reach a statistical significance in its frequency of occurrence between the compliance and non-compliance groups. In the entire study period, 8 out of 40 patients required rescue medication, but there was no association between the status of compliance and the antiemetic guidelines. A total of 22 (55.0 %) patients achieved complete response, which was defined as no vomiting and no use of antiemetic rescue medication, during the study period. The rate of compliance with the prophylactic antiemetic treatment guidelines seemed to be low in patients with hematological malignancy, although the status of the guideline compliance did not always influence the antiemetic effects.

UR - http://www.scopus.com/inward/record.url?scp=85064190964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064190964&partnerID=8YFLogxK

U2 - 10.1691/ph.2019.8889

DO - 10.1691/ph.2019.8889

M3 - Article

C2 - 30940311

AN - SCOPUS:85064190964

VL - 74

SP - 250

EP - 254

JO - Die Pharmazie

JF - Die Pharmazie

SN - 0031-7144

IS - 4

ER -